Comp01 / Dr. Reddy’s - LARVOL DELTA

Dose-Dependent Acute Subjective Psychedelic Effects following COMP360 Psilocybin Across Three Clinical Studies and Its Relationship to Therapeutic Response (ACNP 2022) - "Here we describe the Five-Dimensional Altered States of Consciousness (5D-ASC) questionnaire, assessing subjective psychedelic experience, and the Emotional Breakthrough Inventory (EBI), assessing emotional experience, and their relationships to changes in depressive symptom severity for the three doses employed in COMP001 and for comparison, the results in studies COMP 002 and 003. Improvement in depression symptoms correlated with three dimensions of the of the 5D-ASC and the EBI. This would be expected if a given dose produces a range of psilocin levels, receptor effects and subjective experience. It supports the core pharmacological action that underlies the clinical effect of psilocybin."

Clinical • CNS Disorders • Depression • Psychiatry

Long Term Follow up study for subjects that participated in COMP001 and COMP003 trial (clinicaltrialsregister.eu) - P2; N=150; Ongoing; Sponsor: COMPASS Pathways, Ltd

Clinical • New P2 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3; N=50; Recruiting; Sponsor: Promius Pharma, LLC; Initiation date: Sep 2017 ➔ Aug 2015

Trial initiation date • Biosimilar • Dermatology • Immunology • Psoriasis

Integration between anticipatory blocking and redox signaling by the peroxiredoxin/thioredoxin/thioredoxin-reductase system. (PubMed) - "A more general analysis suggests that the same principles hold in a wide variety of cell types and organisms. We acknowledge grants PEst-C/SAU/LA0001/2013-2014, PEst-OE/QUI/UI0612/2013, FCOMP-01-0124-FEDER-020978 (PTDC/QUI-BIQ/119657/2010) financed by FEDER through the "Programa Operacional Factores de Competitividade, COMPETE" and by national funds through "FCT, Fundação para a Ciência e a Tecnologia"."

Journal • Biosimilar